Shanghai Yutong Pharma, Inc. Completes Definitive Merger with Child Vision, Inc.

Shanghai Yutong Pharma, Inc. Completes Definitive Merger with
Child Vision, Inc. 


NEW YORK, July 15  /PRNewswire-FirstCall/ -- On July 1st, 2005 Shanghai Yutong
Pharmaceuticals, Ltd completed its definitive merger agreement with China Child
Vision, Inc. (OTC:SYUP) (BULLETIN BOARD: SYUP) 

The exchange of shares was calculated at a ratio of 4 shares of Shanghai Yutong
Pharmaceuticals, Ltd for each one share of Child Vision, Inc. The Board had
also agreed to enact a 5 for 1 forward split of the stock to all shareholders
of record.

To reflect the change of control, the Board of Directors elected to change the
name of the Corporation to Shanghai Yutong Pharma, Inc. as well as the trading
symbol to SYUP.

About Shanghai Yutong Pharma, Inc.

Shanghai Yutong Pharma, Inc through its subsidiary Shanghai Yutong
Pharmaceuticals, Ltd. develops Chinese herbal medicines and biological
pharmaceuticals using modern biotechnology and traditional Chinese medical
technology.  Shanghai Yutong operates from a 90,000 square foot GMP-approved
facility and markets over 13 kinds of traditional Chinese medicine with sales
distribution in Hong Kong, Philippines, Singapore and Taiwan.  The Company's
flagship product, Qilisheng Oral Solution, has been granted a U.S. patent.

Legal Disclaimer

The statements contained in this press release contain certain forward looking
statements, including statements regarding the company's expectations,
intentions, strategies and beliefs regarding the future. All statements
contained herein are based upon information available to the company's
management as of the date hereof, and actual results may vary based upon future
events, both within and without the control of the company's management.

   For Further Information:
   Rick Oravec
   
   212-924-3548


DATASOURCE: Shanghai Yutong Pharma, Inc.



CONTACT:  Rick Oravec, , [phone]

Copyright